Interestingly, the four patients with a low BECN1 and high LC3 tumor (two of them underwent chemotherapy and two did not) showed a much better prognosis (not significant; p = 0.37) than the five patients with a high BECN1 and low LC3 tumor (Figure S2E). This evidence concerns the gene MAP1LC3A and neoplasm.